中国僵尸片,亚洲欧美国产另类视频,亚洲精品无码人妻无码,亚洲有码转帖,亚洲欧美精品伊人久久,97精品依人久久久

400-885-9898
更新于 8月27日
智聯(lián)APPAPP
舉報(bào)

IVPU-病理高級(jí)研究員

2.2-3.5萬(wàn)
  • 上海浦東新區(qū)
  • 經(jīng)驗(yàn)不限
  • 博士
  • 全職
  • 招1人

雇員點(diǎn)評(píng)標(biāo)簽

  • 工作環(huán)境好
  • 同事很nice
  • 團(tuán)隊(duì)執(zhí)行強(qiáng)
  • 氛圍活躍
  • 人際關(guān)系好
  • 免費(fèi)班車(chē)
  • 交通便利
  • 非常鍛煉人

職位描述

病理
Responsibility：
1.Establish and improve the pathology technology testing platform, and develop novel application technology platform.
2.Independently conduct and lead research project, analyze experimental results, review and verify experimental records and research reports, and decipher the problems with scientific analysis during studies.
3.Provide services to clients using multiple pathological testing methods. Communicate with clients and provide scientific insight supporting the clients’ projects.
4.Manage the team.
Requirement：
1.PhD with background of Clinical Medicine, Pathology, Laboratory Medicine and Molecular Biology. At least 2 years of working experience in oncology, immunology, clinical pathology analysis are highly preferred.
2.Experimental capabilities in laboratory medicine (molecular pathology testing techniques such as immunohistochemistry, Multiplex IF, FISH, RNAScope, EM, 3D spatial imaging, digital pathology analysis, etc.), and basic tissue sample testing operations (collection, dehydration, fixation, embedding). Proficient in office software, Prism, and other analytical tools of pathology.
3.Proficient in English reading and speaking, strong responsibility ensuring the projects, leadership, work dedicated, skillful communication, collaborative.

工作地點(diǎn)

浦東新區(qū)中國(guó)上海外高橋自貿(mào)區(qū)富特中路288號(hào)

職位發(fā)布者

劉先生/資深人力資源

昨日活躍
立即溝通
公司Logo藥明康德新藥開(kāi)發(fā)有限公司
藥明康德（股票代碼：603259.SH/2359.HK）為全球醫(yī)藥及生命科學(xué)行業(yè)提供一體化、端到端的新藥研發(fā)和生產(chǎn)服務(wù)，在亞洲、歐洲、北美等地均設(shè)有運(yùn)營(yíng)基地。藥明康德通過(guò)獨(dú)特的“CRDMO”業(yè)務(wù)模式，不斷降低研發(fā)門(mén)檻，助力客戶提升研發(fā)效率，為患者帶來(lái)更多突破性的治療方案，服務(wù)范圍涵蓋化學(xué)藥研發(fā)和生產(chǎn)、生物學(xué)研究、臨床前測(cè)試和臨床試驗(yàn)研究等領(lǐng)域。2024年，藥明康德連續(xù)第四年被MSCI評(píng)為ESG（環(huán)境、社會(huì)及管治）AA級(jí)。目前，公司的賦能平臺(tái)正承載著來(lái)自全球30多個(gè)國(guó)家約6,000家合作伙伴的研發(fā)創(chuàng)新項(xiàng)目，致力于將更多新藥、好藥帶給全球病患，早日實(shí)現(xiàn)“讓天下沒(méi)有難做的藥，難治的病”的愿景。
公司主頁(yè)